Genomics and proteomics: application of novel technology to early detection and prevention of cancer

被引:55
|
作者
Michener, CM
Ardekani, AM
Petricoin, EF
Liotta, LA
Kohn, EC
机构
[1] NCI, FDA Clin Prote Program, Pathol Lab, Mol Signalling Lab,Ctr Canc Res, Bethesda, MD 20892 USA
[2] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA
来源
CANCER DETECTION AND PREVENTION | 2002年 / 26卷 / 04期
关键词
molecular-targeted therapies; cancer; laser capture microdissection;
D O I
10.1016/S0361-090X(02)00092-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Advances in molecular biology over the past decade have helped to enhance our understanding of the complex interplay between genetic, transcriptional and translational alterations in human cancers. These molecular changes are the basis for an evolving field of high-throughput cancer discovery techniques using microscopic amounts of patient-based materials. Laser capture microdissection allows pure populations of cells to be isolated from both the tumor and stroma in order to identify subtle differences in RNA and protein expression. Comparative, analysis of these alterations between normal, pre-invasive, and invasive tissue using powerful bioinformatics programs has allowed us to identify novel tumor markers, profile complex protein pathways, and develop new molecular-based therapies. Continued refinement of such high-throughput microtechnologies will enable us to rapidly query patient specimens to identify novel methods for early detection, treatment, and follow-up of a wide array of human cancers. (C) 2002 International Society for Preventive Oncology. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:249 / 255
页数:7
相关论文
共 50 条